First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study – FRONTIERS IN ONCOLOGY

Piedra, A; Martínez-Recio, S; Hernández, A; Morán, T; Arriola, E; Recuero-Borau, J; Cobo, M; Cordeiro, P; Mosquera, J; Fernández, M; García-Campelo, R; Calles, A; Alvarez, R; Zapata-García, M; Isla, D; Callejo, A; Iranzo, P; Serra-López, J; Barba, A; Sullivan, I;...

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes – EUROPEAN JOURNAL OF CANCER

Reck, M; Ciuleanu, TE; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Cheng, Y; Sakai, H; Paz-Ares, L; Lu, S; John, T; Sun, XW; Moisei, A; Taylor, F; Lawrance, R; Zhang, XQ; Sylvester, J; Yuan, Y; Blum,...

One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study – BMJ SUPPORTIVE & PALLIATIVE CARE

Dols, MC; Zambrano, CB; Cabezón-Gutiérrez, L; Chicas-Sett, R; López-Barajas, MIB; Navalón, FJG; Pérez, JLF; Bermúdez, GS; Torres, PT; Mingorance, ID; Marín, AG; Oriol, AL; Lario, AP; Mauriño, PS; Gómez, OH; Muñoz, DM; González, IH; Sanz-Yagüe, A; López, BS –...